A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions

Lymphoma

Interventions

DRUG

[14C]SHR2554

Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.

Trial Locations (1)

The First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06010680 - A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter